Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 1999

View Archived Issues

Wistar Institute discovers mechanism of action of farnesyltransferase inhibitors

Company Profile: Resolution Pharmaceuticals

Celexa approved in Canada

Medeva: year-end 1998 highlights

Alza and Sequus registration statement declared effective

Initial findings reported for CollaGenex's anticancer compound

Cerus gears up for U.S. phase III trials of platelet pathogen inactivation system

Fresenius will distribute Genzyme's Sepra products in select European markets

Sildenafil safe and effective in the treatment of ED in diabetic men

Vertex patents new series with strong and specific p38 kinase-inhibitory activity

Lilly's new orally active anticoagulants

New quinolones from Dong Wha with improved Gram-positive activity and high safety

Tachykinin antagonists in early development at Pfizer

DuPont patents novel CRF antagonists for wide range of conditions

Abbott is also recipient of Prix Galien for its protease inhibitor

S-5920 superior to methylprednisolone in protecting against ARDS

Aastrom cord blood therapy kit receives CE Mark approval

New vasopeptidase inhibitor advances in clinical trials at Bristol-Myers Squibb

Provigil tablets now available in the U.S.

PathoGenesis's CF treatment approved in Canada and Argentina

Potent, selective and orally bioavailable 5-ht6 receptor antagonist presented by SB

Early clinical results presented for ABX-IL-8 in psoriasis

Antiarthritic effects, mechanism and GI safety of S-2474 evaluated in rat model

NeoTherapeutics expands Neotrofin clinical trials internationally

FDA says KeraVision's treatment for myopia approvable

Celgene initiates Canadian clinical trial program for chirally pure form of Ritalin

Ligand introduces second new product this month

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...